Outlook Therapeutics Gets FDA Approval for LYTENAVA in Wet AMD Treatment
On July 29, 2026, the U.S. Food and Drug Administration approved Outlook Therapeutics Inc.'s (OTLK) ONS-5010/LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for treating neovascular age-related macular degeneration (wet AMD). This marks a significant regulatory milestone after three prior rejections. The approval is expected to grant LYTENAVA 12 years of Reference Product Exclusivity under the Biologics Price Competition and Innovation Act. LYTENAVA addresses an unmet need in retina care, where bevacizumab has been widely used off-label for over two decades due to a lack of FDA-approved ophthalmic formulations. The drug is now positioned as the leading therapy in this space, with Outlook Therapeutics planning its commercial launch by year-end. The U.S. anti-VEGF retina market generates approximately $8.5 billion annually and involves millions of intravitreal injections each year. With LYTENAVA's approval, the company aims to expand patient access, improve reimbursement strategies, and build a specialized sales team focused on retinal care.
Tickers: $OTLK
Topics: biotech drug approval FDA ophthalmology